HOWL Werewolf Therapeutics Inc.

14.98
+0.02  (+0%)
Previous Close 14.96
Open 14.65
52 Week Low 11.23
52 Week High 23.99
Market Cap $413,140,356
Shares 27,579,463
Float 19,130,163
Enterprise Value $244,191,766
Volume 77,414
Av. Daily Volume 27,310
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
WTX-124 and KEYTRUDA (pembrolizumab)
Solid tumors
Phase 1
Phase 1
Phase 1 trial to be initiated.
WTX-124
Solid Tumors
Phase 1
Phase 1
IND filing 1H 2022.
WTX-330
Solid tumors
Phase 1
Phase 1
IND filing 1H 2022.

Latest News

  1. -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program-

    -On Track to File Two INDs in First Half of 2022-

    CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today provided a business update and reported financial results for the quarter ended September 30, 2021.

    "Werewolf Therapeutics continues to make significant progress advancing and executing across our pipeline and we are on track to file INDs for our two lead INDUKINE™ product candidates, WTX-124 and WTX-330, in…

    -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program-

    -On Track to File Two INDs in First Half of 2022-

    CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today provided a business update and reported financial results for the quarter ended September 30, 2021.

    "Werewolf Therapeutics continues to make significant progress advancing and executing across our pipeline and we are on track to file INDs for our two lead INDUKINE™ product candidates, WTX-124 and WTX-330, in the first half of 2022," said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "We have also achieved several important corporate milestones, including the announcement of our clinical trial collaboration and supply agreement with Merck to evaluate WTX-124 in combination with KEYTRUDA®."

    Merck Collaboration: In August 2021, Werewolf announced its entry into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE product candidate, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy. The planned clinical trial will be conducted by Werewolf and is designed to evaluate the safety and preliminary efficacy of WTX-124 as a monotherapy and in combination with KEYTRUDA in patients with solid tumors.

    Expanded the Board of Directors: In October 2021, Werewolf appointed Meeta Chatterjee, Ph.D., as a member of the Board of Directors. Dr. Chatterjee brings over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities.

    Upcoming preclinical presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021 in Washington, DC: Werewolf will present posters on its lead programs WTX-124 (Poster #718), WTX-330 (Poster #715) and WTX-613 (Poster #723) describing the design and preclinical evaluation of Werewolf's IL-2, IL-12 and IFN-a INDUKINE™ molecules.

    Third Quarter 2021 Financial Highlights

    • Cash position: As of September 30, 2021, cash and cash equivalents were $170.4 million, compared to $92.6 million as of December 31, 2020. The increase was primarily due to the receipt of $109.2 million in net proceeds from the initial public offering completed in May 2021, offset by operating expenses incurred during the period. Given the strength of its balance sheet, Werewolf expects its existing cash and cash equivalents to enable the funding of its operating expenses and capital expenditure requirements through at least the second quarter of 2023.



    • Research and development expenses: Research and development expenses were $9.8 million for the third quarter of 2021, compared to $4.8 million for the same period in 2020. The increase in research and development expenses was primarily due to increased manufacturing, contract research organization, and personnel expenses incurred to advance the Company's product candidates WTX-124, WTX-330 and WTX-613 and expand research and development activities.



    • General and administrative expenses: General and administrative expenses were $4.0 million for the third quarter of 2021, compared to $1.2 million for the same period in 2020. The increase in general and administrative expenses was primarily due to increased personnel, professional services, and other operating costs attributable to operating as a public company.



    • Net loss: Net loss was $13.8 million for the third quarter of 2021, compared to $6.1 million for the same period in 2020.

    About Werewolf Therapeutics:

    Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risk and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf's strategy, future operations, prospects, plans, objectives of management, the expected timeline for submitting investigational new drug applications and its sufficiency of its cash resources constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and our ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; the Company's ability to obtain sufficient cash resources to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on the Company's business and operations; as well as the risks and uncertainties identified in the "Risk Factors" section of the Company's most recent Form 10-Q filed with the Securities and Exchange Commission ("SEC") and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.



    Werewolf Therapeutics, Inc.

    Condensed Consolidated Statements of Operations (unaudited)

    (amounts in thousands, except per share data)

     Three Months Ended

    September 30,
     Nine Months Ended

    September 30,
     2021 2020 2021 2020
    Operating expenses:       
    Research and development$9,787  $4,812  $21,869  $11,355 
    General and administrative4,008  1,241  10,334  3,657 
    Total operating expenses13,795  6,053  32,203  15,012 
    Operating loss(13,795) (6,053) (32,203) (15,012)
    Other income (expense)37  (15) 89  7,374 
    Net loss(13,758) (6,068) (32,114) (7,638)
    Accretion of redeemable convertible preferred stock to redemption value    (151,942) (31)
    Net loss attributable to common stockholders$(13,758) $(6,068) $(184,056) $(7,669)
    Net loss per share attributable to common stockholders, basic and diluted$(0.51) $(6.61) $(11.89) $(8.03)
    Weighted-average common shares outstanding, basic and diluted27,188  918  15,485  955 

    Werewolf Therapeutics, Inc.

    Selected Condensed Consolidated Balance Sheet Data (unaudited)

    (amounts in thousands)

     September 30, 2021 December 31, 2020
    Cash and cash equivalents$170,438 $92,570 
    Working capital$166,629 $87,630 
    Total assets$178,375 $96,398 
    Total stockholders' equity (deficit)$169,303 $(51,863)
           

    Investor Contact:

    Jonathan M. Nugent

    Stern IR

    212.698.8698

    Media Contact:

    Amanda Sellers

    VERGE Scientific Communications

    301.332.5574

    Company Contact:

    Ellen Lubman

    Chief Business Officer

    Werewolf Therapeutics



    Primary Logo

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will present at the following investor conferences:

    Jefferies Global Healthcare Conference on Thursday, November 18th at 3:00am EST

    Evercore ISI HealthCONx Conference on Tuesday, November 30th at 10:30am EST

    Access to the live webcast of these events, as well as an archived recording, will be available under the "Events" tab on the investor relations section of the Werewolf Therapeutics website at: https://investors.werewolftx.com/news-and-events/events

    CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will present at the following investor conferences:

    Jefferies Global Healthcare Conference on Thursday, November 18th at 3:00am EST

    Evercore ISI HealthCONx Conference on Tuesday, November 30th at 10:30am EST

    Access to the live webcast of these events, as well as an archived recording, will be available under the "Events" tab on the investor relations section of the Werewolf Therapeutics website at: https://investors.werewolftx.com/news-and-events/events.

    About Werewolf Therapeutics, Inc.

    Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

    To learn more visit  https//werewolftx.com.

    Investor Contact:

    Jonathan Nugent

    Managing Director

    Stern IR

    Media Contact:

    Amanda Sellers

    VERGE Scientific Communications

    301.332.5574

     

    Company Contact:

    Ellen Lubman

    Chief Business Officer

    Werewolf Therapeutics



    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Meeta Chatterjee, Ph.D., Senior Vice President of Global Business Development at Legend Biotech Corporation, as a member of its board of directors.

    "I am thrilled to join Werewolf's board of directors as the company prepares to advance investigational new drug applications for its two lead INDUKINETM product candidates, WTX-124 and WTX-330, for the treatment of solid tumors," said Dr. Chatterjee. "We are just beginning to understand…

    CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Meeta Chatterjee, Ph.D., Senior Vice President of Global Business Development at Legend Biotech Corporation, as a member of its board of directors.

    "I am thrilled to join Werewolf's board of directors as the company prepares to advance investigational new drug applications for its two lead INDUKINETM product candidates, WTX-124 and WTX-330, for the treatment of solid tumors," said Dr. Chatterjee. "We are just beginning to understand the power of the PREDATORTM protein engineering platform and its potential to generate a broad pipeline of systemically delivered, conditionally activated molecules that may stimulate immunity and provide potentially safer and more efficacious treatments for cancer patients."

    "I am pleased to welcome Dr. Chatterjee to our board of directors at this exciting time for our company," added Luke Evnin, Ph.D., Chairman of the Board of Directors and co-founder of Werewolf Therapeutics. "Meeta's deep and proven experience across biopharmaceutical R&D, operations, corporate strategy and business development represents a critical addition to our board's skill set."

    Dr. Chatterjee joins the Werewolf board of directors with more than 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities. Prior to her current role as the Senior Vice President of Global Business Development at Legend Biotech Corporation, she served as Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group at Merck Research Labs, where she oversaw discovery and late-stage transactions worldwide, as well as early-stage transactions in key geographies, and was responsible for Merck's BD&L governance, oversight, and control as well as out-licensing efforts. Dr. Chatterjee has led or contributed to a number of transactions or collaborations, has led research efforts in the areas of hypertension, atherosclerosis, and obesity, and was an integral contributor to the discovery of ZETIA® and ZONTIVITY®. Dr. Chatterjee completed her undergraduate education at St. Xavier's University in Ahmedabad, India, and Rutgers University (B.A., Honors Physics), received her Ph.D. in Physiology from Rutgers University, and completed a postdoctoral fellowship in the Department of Physiology at the University of Virginia School of Medicine. Dr. Chatterjee is active in industry and licensing-focused organizations.

    About Werewolf Therapeutics, Inc.

    Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

    To learn more visit www.werewolftx.com.

    Investor Contact:

    Ellen Lubman

    Chief Business Officer

    Werewolf Therapeutics

    Media Contact:

    Amanda Sellers

    VERGE Scientific Communications

    301.332.5574

       



    Primary Logo

    View Full Article Hide Full Article
  4. CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that it will present preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually.

    "We are excited to share additional preclinical data demonstrating the potential of our INDUKINE™ molecules to drive targeted anti-tumor immune responses with IL-2 and IL-12 cytokines, as well as interferon alpha," said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer…

    CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that it will present preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually.

    "We are excited to share additional preclinical data demonstrating the potential of our INDUKINE™ molecules to drive targeted anti-tumor immune responses with IL-2 and IL-12 cytokines, as well as interferon alpha," said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. "We plan to include results from two of the presented studies in our investigational new drug (IND) applications for WTX-124 and WTX-330, respectively, which we expect to file during the first half of 2022."

    Poster Presentations

    Details on the three poster presentations are as follows:

    Title/Abstract number: WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity in murine syngeneic cancer models. Abstract #718.

    Title/Abstract number: WTX-330, a conditionally activated IL-12 INDUKINE™ therapy, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models. Abstract #715.

    Title/Abstract number: WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models. Abstract #723.

    The full abstracts will be made available on the SITC website on November 9, 2021.

    About Werewolf Therapeutics, Inc.

    Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE™ molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

    To learn more visit www.werewolftx.com.

    Investor Contact:

    Ellen Lubman

    Chief Business Officer

    Werewolf Therapeutics

    Media Contact:

    Amanda Sellers

    VERGE Scientific Communications

    301.332.5574



    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that members of its leadership team will present at the Next-Gen Cytokine Therapeutics Summit on September 22.

    Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf, will deliver a presentation entitled, "Pioneering the Development of Therapeutics Engineered to Overcome Key Challenges and Unlock the Full Potential of Cytokine Therapeutics," at 4:20 pm EDT on September 22.

    Following Dr. Seidel-Dugan's presentation, Werewolf's Chief Medical…

    CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that members of its leadership team will present at the Next-Gen Cytokine Therapeutics Summit on September 22.

    Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf, will deliver a presentation entitled, "Pioneering the Development of Therapeutics Engineered to Overcome Key Challenges and Unlock the Full Potential of Cytokine Therapeutics," at 4:20 pm EDT on September 22.

    Following Dr. Seidel-Dugan's presentation, Werewolf's Chief Medical Officer, Randi Isaacs, M.D., will participate in a Summit panel discussion at 4:50 pm EDT entitled, "Where does the Future Lie for Cytokine Therapies?" More information on attending the Summit can be found at https://www.cytokinetherapeutics.com/.

    About Werewolf Therapeutics, Inc.

    Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

    To learn more visit www.werewolftx.com.

    Investor Contact:

    Ellen Lubman

    Chief Business Officer

    Werewolf Therapeutics

    Media Contact:

    Amanda Sellers

    VERGE Scientific Communications

    301.332.5574

     



    Primary Logo

    View Full Article Hide Full Article
View All Werewolf Therapeutics Inc. News